Unbound MEDLINE

Prevention of postoperative recurrence of Crohn's disease.

Abstract

BACKGROUND
Up to 75% of patients with Crohn's disease (CD) will have intestinal resection during their life. Most patients will, however, develop postoperative recurrence (endoscopic, clinical or surgical). Several medical and surgical strategies have been attempted to prevent postoperative recurrence. This review evaluates the efficacy of different drug regimens and surgical techniques in the prevention of clinical, endoscopic and surgical postoperative recurrence of CD.
METHODS
A literature search for randomized controlled trials on medical or surgical interventions was performed. The endpoints for efficacy were clinical, endoscopic and surgical recurrence. Meta-analyses were performed in case two or more RCTs evaluated the same drug or surgical technique.
RESULTS
Mesalamine is more effective in preventing clinical recurrence than placebo (P=0,012), as well as nitroimidazolic antibiotics at one year follow-up (P<0.001) and thiopurines (P=0.018). Nitroimidazolic antibiotics are also more effective than placebo in preventing endoscopic recurrence (P=0.037), as well as thiopurines (P=0.015) and infliximab (P=0.006). Budenoside, probiotics, Interleukin-10 nor any of the different surgical procedures showed any significant difference compared to placebo in postoperative recurrence rates of CD.
CONCLUSION
Among the different drug regimens and surgical techniques, only thiopurines and nitroimidazolic antibiotics are able to reduce postoperative clinical as well as endoscopic recurrence of CD. Mesalamine and infliximab also seem to be superior to placebo in preventing clinical recurrence and endoscopic recurrence, respectively. There is a paucity of trials evaluating long-term follow-up and prevention of surgical recurrence of CD.

Links

  • Aggregator Full Text
  • Authors

    van Loo ES, Dijkstra G, Ploeg RJ, Nieuwenhuijs VB

    Institution

    Department of Surgery, Scheper Ziekenhuis Emmen, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. e.s.van.loo@umcg.nl

    Source

    Journal of Crohn's & colitis 6:6 2012 Jul pg 637-46

    MeSH

    6-Mercaptopurine
    Anastomosis, Surgical
    Anti-Bacterial Agents
    Anti-Inflammatory Agents, Non-Steroidal
    Antibodies, Monoclonal
    Azathioprine
    Crohn Disease
    Gastrointestinal Agents
    Humans
    Immunosuppressive Agents
    Interleukin-10
    Intestine, Small
    Laparoscopy
    Mesalamine
    Nitroimidazoles
    Probiotics
    Recurrence
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Review

    Language

    eng

    PubMed ID

    22398096